These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 12851770)

  • 21. Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.
    Hashim H; Abrams P
    Drugs; 2004; 64(15):1643-56. PubMed ID: 15257626
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The medical treatment of overactive bladder, including current and future treatments.
    Athanasopoulos A; Cruz F
    Expert Opin Pharmacother; 2011 May; 12(7):1041-55. PubMed ID: 21299469
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?
    Finney SM; Andersson KE; Gillespie JI; Stewart LH
    BJU Int; 2006 Sep; 98(3):503-7. PubMed ID: 16925744
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How do medications used to treat urinary incontinence affect the cerebral function of the elderly?].
    Goepel M; Steinwachs KC
    Urologe A; 2007 Apr; 46(4):387-8, 390-2. PubMed ID: 17377763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Urgency, botulinum toxin and how botulinum toxin can help urgency.
    Chancellor MB
    J Urol; 2005 Sep; 174(3):818. PubMed ID: 16093961
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis.
    Millard RJ; Halaska M
    Curr Med Res Opin; 2006 Jan; 22(1):41-8. PubMed ID: 16393429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II drugs that target cholinergic receptors for the treatment of overactive bladder.
    Zacche MM; Giarenis I; Cardozo L
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1365-74. PubMed ID: 24899225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and tolerability of tolterodine for the treatment of overactive bladder in adults.
    Roberts RG; Garely AD; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S158-62. PubMed ID: 16161389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Overactive bladder: modulating the effects of antimuscarinic therapy].
    Palleschi G; Tubaro A; Miano L
    Minerva Urol Nefrol; 2005 Dec; 57(4):237-45. PubMed ID: 16247346
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of overactive bladder syndrome.
    Srikrishna S; Robinson D; Cardozo L; Vella M
    Postgrad Med J; 2007 Jul; 83(981):481-6. PubMed ID: 17621619
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimuscarinics and overactive bladder: other mechanism of action.
    Yamaguchi O
    Neurourol Urodyn; 2010; 29(1):112-5. PubMed ID: 19693952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction.
    Andersson KE; Campeau L; Olshansky B
    Br J Clin Pharmacol; 2011 Aug; 72(2):186-96. PubMed ID: 21595741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity.
    Glavind K; Chancellor M
    Int Urogynecol J; 2011 Aug; 22(8):907-17. PubMed ID: 21468739
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Case series data to encourage randomized trials of bladder retraining compared to antimuscarinic agents.
    Ghei M; Miller R; Malone-Lee J
    J Urol; 2006 Apr; 175(4):1411-5; discussion 1415-6. PubMed ID: 16516010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.
    Perimenis P; Konstantinopoulos A; Giannitsas K; Athanasopoulos A
    Expert Opin Pharmacother; 2006 Apr; 7(5):539-44. PubMed ID: 16553569
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Review of cognitive impairment with antimuscarinic agents in elderly patients with overactive bladder.
    Wagg A; Verdejo C; Molander U
    Int J Clin Pract; 2010 Aug; 64(9):1279-86. PubMed ID: 20529135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antimuscarinic mechanisms and the overactive detrusor: an update.
    Andersson KE
    Eur Urol; 2011 Mar; 59(3):377-86. PubMed ID: 21168951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trospium chloride treatment of overactive bladder.
    Biastre K; Burnakis T
    Ann Pharmacother; 2009 Feb; 43(2):283-95. PubMed ID: 19193592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of urge-predominant mixed urinary incontinence with tolterodine extended release: a randomized, placebo-controlled trial.
    Khullar V; Hill S; Laval KU; Schiøtz HA; Jonas U; Versi E
    Urology; 2004 Aug; 64(2):269-74; discussion 274-5. PubMed ID: 15302476
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis.
    Chapple C; Khullar V; Gabriel Z; Dooley JA
    Eur Urol; 2005 Jul; 48(1):5-26. PubMed ID: 15885877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.